Sandostatin lar and Bile duct obstruction - a phase IV clinical study of FDA data

Summary:

Bile duct obstruction is found among people who take Sandostatin lar, especially for people who are male, 60+ old, have been taking the drug for 1 - 2 years.

The phase IV clinical study analyzes which people take Sandostatin lar and have Bile duct obstruction. It is created by eHealthMe based on reports of 35,192 people who have side effects when taking Sandostatin lar from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Jul, 02, 2023

35,192 people reported to have side effects when taking Sandostatin lar.
Among them, 204 people (0.58%) have Bile duct obstruction.

What is Sandostatin lar?

Sandostatin lar has active ingredients of octreotide acetate. It is often used in acromegaly. eHealthMe is studying from 35,253 Sandostatin lar users for its effectiveness, alternative drugs and more.

What is Bile duct obstruction?

Bile duct obstruction (blockage in the tubes that carry bile from the liver to the gallbladder) is found to be associated with 1,238 drugs and 593 conditions by eHealthMe.

Number of Sandostatin lar and Bile duct obstruction reports submitted per year:

Could Sandostatin lar cause Bile duct obstruction?

* Approximation only. Some reports may have incomplete information.

Do you take Sandostatin lar and have Bile duct obstruction?

Check whether Bile duct obstruction is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

Saif MW, "Rheumatoid arthritis associated with the use of Sandostatin? LAR? depot in a patient with pancreatic neuroendocrine tumor", An association or a coincidence? The first case report, 2017 Jan .
Azkur D, Yoldas T, Toyran M, Kocabas CN, "A pediatric case of anaphylaxis due to octreotide", Asian Pacific journal of allergy and immunology, 2011 Dec .

Related studies

How severe was Bile duct obstruction and when was it recovered:

Bile duct obstruction in Sandostatin lar

Expand to all the drugs that have ingredients of octreotide acetate:

Bile duct obstruction and drugs with ingredients of octreotide acetate

Alternative drugs to, pros and cons of Sandostatin lar:

Sandostatin lar (35,253 reports)

Common Sandostatin lar side effects:

Diarrhea: 8,204 reports
High blood pressure: 8,144 reports
Fatigue (feeling of tiredness): 6,857 reports
Malaise (a feeling of general discomfort or uneasiness): 5,396 reports
Pain: 5,065 reports
Weakness: 4,959 reports
Abdominal pain: 4,709 reports

Browse all side effects of Sandostatin lar:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Bile duct obstruction treatments and more:

Bile duct obstruction (3,332 reports)

COVID vaccines that are related to Bile duct obstruction:

Common drugs associated with Bile duct obstruction:

All the drugs that are associated with Bile duct obstruction:

Bile duct obstruction (1,238 drugs)

Common conditions associated with Bile duct obstruction:

Rheumatoid arthritis: 232 reports
High blood pressure: 172 reports
Type 2 diabetes: 141 reports
Pain: 114 reports
Multiple sclerosis: 110 reports

All the conditions that are associated with Bile duct obstruction:

Bile duct obstruction (593 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on octreotide acetate (the active ingredients of Sandostatin lar) and Sandostatin lar (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.